Integrin beta3 blockade with abciximab and protection from myocardial ischemic events.
Conrad
M E
ME
Umbreit
J N
JN
Moore
E G
EG
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000187:drug effects*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D039661:Integrin beta3; D016023:Integrins / Q000037:antagonists & inhibitors*; D017202:Myocardial Ischemia / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010980:Platelet Membrane Glycoproteins / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D007140:Immunoglobulin Fab Fragments; D039661:Integrin beta3; D016023:Integrins; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D000077284:Abciximab